1. Home
  2. RMI vs NYXH Comparison

RMI vs NYXH Comparison

Compare RMI & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RiverNorth Opportunistic Municipal Income Fund Inc.

RMI

RiverNorth Opportunistic Municipal Income Fund Inc.

N/A

Current Price

$12.96

Market Cap

87.4M

Sector

Finance

ML Signal

N/A

Logo Nyxoah SA

NYXH

Nyxoah SA

N/A

Current Price

$0.85

Market Cap

91.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RMI
NYXH
Founded
N/A
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Finance/Investors Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
87.4M
91.6M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
RMI
NYXH
Price
$12.96
$0.85
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $2.80
AVG Volume (30 Days)
20.9K
★ 214.4K
Earning Date
01-01-0001
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$234.49
Revenue Next Year
N/A
$98.07
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.07
$0.80
52 Week High
$16.36
$5.39

Technical Indicators

Market Signals
Indicator
RMI
NYXH
Relative Strength Index (RSI) 29.11 33.70
Support Level N/A $0.80
Resistance Level $14.17 $0.97
Average True Range (ATR) 0.21 0.04
MACD -0.09 0.02
Stochastic Oscillator 5.22 45.97

Price Performance

Historical Comparison
RMI
NYXH

About RMI RiverNorth Opportunistic Municipal Income Fund Inc.

RiverNorth Opportunistic Municipal Income Fund, Inc. is a diversified, closed-end management investment company. Its investment objective is to seek current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: